Fatih Bıçaklıoğlu

Urologist ,MD , FEBU, Kartal Dr Lutfi Kirdar City Hospital

[Fatih Bıçaklıoğlu @bicaklioglu_f]

SUPINE mini-PNL for HORSESHOE KIDNEY 👍👍 with our chief of urology @hrizaaydin in @trabzonkeah. Many thanks again to @ytanidir and @MarmaraUroloji for sharing their knowledge with us 🙋‍♂️

[Kemal SARICA @uroksarica]

Another IAU endorsed endourology workshop focusing on "Supermini-PNL" in stone management.All aspects will be discussed interactively by the experts with presentations and live surgery by the master Prof G.Zeng. IAU based educational activities will continue with full force..

[Dr_KevinZorn @Dr_KevinZorn]

#PURABOND -novel agent to provide fast, reliable hemostasis ⬇️ post-op bleeding, dysuria. Faster healing. Helping urologists & patients SLEEP BETTER after #BPH surgery. It’s 2026 >dependable hemostasis should be standard & enhanced mucosal resurfacing must be our goal. #EAU26

[Dr Bivek Kumar, Mch (URO.) @BKidneydoc]

🧠 EAU 2026: What’s New in Prostate Cancer Care?
📍 Practice-changing updates every clinician should know

🔹 1. Risk Stratification Reboot
🧭 Intermediate BCR risk now split into favourable vs unfavourable
→ Alters adjuvant therapy decisions & follow-up intensity

🔹 2. Imaging Gets Smarter
🧠 PSMA-PET/CT now recommended for staging intermediate-risk PCa
🧠 MRI-first endorsed for screening & biopsy targeting
→ Earlier, more accurate staging becomes standard

🔹 3. Biopsy Strategy Updated
💉 Transperineal biopsy preferred over transrectal
→ Safer, cleaner, more precise sampling
📊 New flowchart for biopsy & imaging in BCR

🔹 4. Systemic Therapy in mHSPC
💊 Triplet therapy (ADT + docetaxel + ARPI) now formally recommended
💊 ADT + ARPI preferred in low-volume metachronous mHSPC
→ Intensified systemic care, MDT discussion now mandatory

🔹 5. CRPC & Neuroendocrine PCa
🧬 Tailored sequencing after ARPI/chemo
🧬 Neuroendocrine PCa treated as distinct entity
→ Less extrapolation, more precision

🔹 6. Supportive Care Matters
🦴 Bone-protective agents now standard with long-term ADT ± ARPI
→ Bone health is no longer optional

📌 What Changes ?
✅ re-label BCR risk groups
✅ stage smarter with PSMA-PET
✅ biopsy transperineally
✅ intensify systemic therapy
✅ embed bone health & MDT into routine care

Dr Bivek Kumar - Urologist

[Julian Chavarriaga @chavarriagaj]

#EAU26 @ChrisSweens1: the field is reaching a consensus in mHSPC.
ADT + ARPI for nearly all patients, then personalize intensification:
• SBRT for low-volume
• Prostate RT in synchronous disease
• Docetaxel if high-volume and chemofit

🕒 The hope for the future: biomarkers to guide therapy, global access, and drug prices coming down so evidence-based care becomes feasible worldwide.
@uroweb @UroToday

[Julian Chavarriaga @chavarriagaj]

#EAU26 ctDNA to guide adjuvant therapy after cystectomy?
•Conventional risk stratification may not be enough.
ctDNA positivity strongly predicts recurrence after RC
• Christensen et al: ctDNA+ → markedly higher relapse risk
• IMvigor010: benefit from adjuvant IO mainly in ctDNA+ pts
✅IMvigor011: ctDNA-guided atezolizumab improved DFS in ctDNA+ pts
@JBjerggaard: Yes, we are ready to guide adjuvant therapy with ctDNA!
@uroweb @UroToday

[Morgan Roupret @MRoupret]

#EAU26 London – Take-Home Messages on Muscle-Invasive and Advanced Urothelial Cancer 🫵
Honoured to be part of the scientific committee office of the congress and to  share today at the hashtag#EAU26 in London a short “Best of the Best” overview of the most impactful data shaping the management of muscle-invasive bladder cancer (MIBC) and metastatic urothelial carcinoma.
Here are my key take-home messages:
1️⃣ Radical cystectomy remains central in MIBC (in 2026)
Despite the rapid development of systemic therapies and bladder-preserving strategies, radical cystectomy continues to be the cornerstone of curative treatment. Current diagnostic tools (imaging, endoscopy) still lack the accuracy needed to safely omit surgery in most patients.
2️⃣ Biomarkers are coming – but not ready to replace surgery
Circulating tumor DNA (ctDNA) is emerging as a powerful tool to identify minimal residual disease and systemic relapse risk. However, ctDNA currently reflects systemic disease rather than local bladder tumor burden. We are not yet able to confidently equate clinical complete response with pathological complete response.
3️⃣ EV + Pembrolizumab is reshaping the peri-operative landscape
Results from KEYNOTE-B15 / EV-304 and KEYNOTE-905 / EV-303 suggest that ADC + immune checkpoint inhibitor combinations may significantly improve outcomes compared with standard cisplatin-based chemotherapy.
But an essential message remains:
➡️ Systemic therapy must be integrated with radical cystectomy, not replace it.
4️⃣ In metastatic urothelial cancer: EV + Pembro is the new frontline standard
Data continue to confirm that enfortumab vedotin + pembrolizumab provides major improvements in PFS and OS versus platinum chemotherapy.
➡️ The paradigm has shifted: EVP first – ask questions later.
5️⃣ The next challenges
• Optimising toxicity management of EVP
• Identifying patients with early progression
• Integrating biomarkers and real-world evidence
• Defining the future role of chemotherapy in a rapidly evolving landscape
Exciting times in urothelial cancer, where surgery, systemic therapy, biomarkers and innovation are finally converging.
#EAU26 #BladderCancer #UrothelialCancer #MIBC #Oncology #Urology @Uroweb @AFUrologie

[Tom Powles @tompowles1]

Nectin-4 is expressed in almost all urothelial cancers . Nectin-4 fluorescence imaging during cystoscopy makes sense and seems to work well (see below) #EAU26 @urotoday . This potentially improves diagnostic accuracy. It would be good to generate large randomized data. @OncoAlert

[Julian Chavarriaga @chavarriagaj]

#EAU26 Does bladder preservation really improve QoL?
Dr. Gessner reviews the CISTO study (n=570) BST vs RC in recurrent high-grade NMIBC.
🔹 Physical function at 12 mo: similar between BST and RC
🔹 RC: better emotional function, ↓ anxiety/depression, ↓ financial burden
🔹 BST: better bowel & sexual outcomes
📊 Oncological outcomes:
• CSS similar (99% BST vs 96% RC)
• BST → higher recurrence rates
• RC → higher perioperative toxicity (90-day mortality ~2.5%)
@uroweb @UroToday

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

@tompowles1 @weoncologists @Uromigos @kalasri3 Thanks for the shoutout Tom.
We need to help our patients and deliver a unified message:
The OS advantage seen with EV+P
relies on consolidation with Radical
Cystectomy + PLND
(not observation, not TMT)
#EAU26

[@DocMeetings - Urology @docmeetings]

PRostate cancer guidelines 2026 update. Digital rectal exam NOW no more recommended for Asymptomatic men

SO NO MORE FOR Screening

Important for standing and for early diagnosis for SYMPTOMS only @Uroweb

[Joan Palou Redorta @joanfundi]

Consider #Cystectomy in older population: better survival than TMT. Why not to perform Cystectomy and ureterocutaneostomy! Avoiding complications and #mortality in frail patients wit MI #bladdercancer . #EAU25. ⁦@FPuigvert⁩.

[Baris Turkbey MD @radiolobt]

📣I am happy to share our Team's new publication "Predicting 18F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical Recurrence"
https://t.co/Aa4P54WKJf
👍Congratulations to @KaterinaHoowon and our amazing multi-disciplinary Team
#prostatecancer #molcularimaging #CancerResearch #MedTwitter #TeamScience

[Hao Nguyen @haognguyen]

Happy to share our research on PSMA guided surgery. This innovative approach has the potential to revolutionize cancer detection beyond the prostate, identifying cases that would have gone unnoticed with existing technology

https://t.co/yW7bP0Qpo5$. @pcarroll_ @IntuitiveSurg

[Fatih Bıçaklıoğlu @bicaklioglu_f]

@drozanbozkurt @so_uro @UropediaUCD @SocietyGURS @SUSTurkey @EAUYAUrology @EAU_YAURecon @Uroweb Çok güzel olmuş👏🏻👏🏻👏🏻elinize sağlık

[Fatih Bıçaklıoğlu @bicaklioglu_f]

@UrologoEdgar Left pcnl stone free( luckily only with 1 lower pole access), right pcnl + rırs (2 session, still residuals in the lower pole)

[Urologic Oncology @UrolOncol]

Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer https://t.co/SOfWwrNilv

[Fatih Bıçaklıoğlu @bicaklioglu_f]

@dr_khadgi 👏🏻👏🏻👏🏻

[Fatih Bıçaklıoğlu @bicaklioglu_f]

@drahmetsahan 👏🏻👏🏻👏🏻

[S. Duke Herrell, MD @RoboDuke1]

"3rd lane" of Urology robotic surgery opens FDA clears J&J’s Monarch flexible robot for urology.Virtuoso Surgical will open the "4th lane" Rigid Endoscopy w/ revolutionizing the tools and capabilities. VSI may provide an even larger impact across many procedures and specialties.

[Fatih Bıçaklıoğlu @bicaklioglu_f]

@RoboDuke1 👏🏻👏🏻👏🏻